Skip to main content

Table 1 Characteristics of study participants at enrollment. All data are shown as a number (%) unless otherwise indicated

From: BRAzil magnesium (BRAMAG) trial: a double-masked randomized clinical trial of oral magnesium supplementation in pregnancy

Characteristic at enrollment

Magnesium citrate

(n = 407)

Placebo

(n = 422)

P-value

Mean (SD) maternal age, years

26.9 (5.4)

27.2 (5.8)

0.53

Mean (SD) gestational age at entry, weeks

15.1 (3.6)

15.6 (3.8)

0.05

Lives with partner

211 (51.8)

188 (44.5)

0.04

Completed schooling beyond grade 8

379 (93.3)

388 (91.9)

0.44

Currently employed

221 (54.3)

220 (52.1)

0.53

Alcohol use disorder

8 (2.0)

12 (2.8)

0.41

Current smoker

5 (1.2)

11 (2.6)

0.15

Current illicit drug use

3 (0.7)

5 (1.2)

0.73

Pre-pregnancy body mass index, kg/m2

  < 18.5

13 (3.2)

11 (2.6)

0.89

18.5 to 24.9

162 (39.8)

171 (40.7)

25.0 to 29.9

136 (33.4)

146 (34.8)

  ≥ 30.0

96 (23.6)

92 (21.9)

Pre-pregnancy chronic hypertension

50 (22.1)

60 (24.4)

0.59

Gestational diabetes mellitus in a previous pregnancy

11 (4.9)

18 (7.3)

0.27

Preterm birth in a previous pregnancy

38 (9.6)

38 (9.3)

0.87

Mean (SD) serum magnesium concentration, mg/dL

1.8 (0.2)

1.8 (0.2)

0.94

Serum magnesium deficiency < 1.8 mg/dL

194 (47.9)

219 (52.1)

0.22

Mean (SD) serum creatinine concentration, mg/dL

0.5 (0.2)

0.5 (0.1)

0.80